{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:26:36Z","timestamp":1790346396695,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,4,12]],"date-time":"2013-04-12T00:00:00Z","timestamp":1365724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            To assess the impact of lymphovascular invasion (\n                            <jats:styled-content style=\"fixed-case\">LVI<\/jats:styled-content>\n                            ) on upper urinary tract urothelial carcinomas (\n                            <jats:styled-content style=\"fixed-case\">UTUCs<\/jats:styled-content>\n                            ) in a multicentre study on cancer\u2010specific survival (\n                            <jats:styled-content style=\"fixed-case\">CSS<\/jats:styled-content>\n                            ), recurrence\u2010free survival and metastasis\u2010free survival (\n                            <jats:styled-content style=\"fixed-case\">MFS<\/jats:styled-content>\n                            ).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            To show the negative impact of\n                            <jats:styled-content style=\"fixed-case\">LVI<\/jats:styled-content>\n                            for patients with\n                            <jats:styled-content style=\"fixed-case\">pN0<\/jats:styled-content>\n                            \/x disease and to stratify these patients into risk groups for metastatic relapse.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>A multicentre retrospective study was performed on patients who underwent radical nephroureterectomy between 1995 and 2010.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:styled-content style=\"fixed-case\">LVI<\/jats:styled-content>\n                            status was evaluated as a prognostic factor for survival using univariate and multivariate\n                            <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\n                            ox regression analysis.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Overall, 551 patients were included and were divided into two groups: those without\n                            <jats:styled-content style=\"fixed-case\">LVI<\/jats:styled-content>\n                            (\n                            <jats:styled-content style=\"fixed-case\">LVI<\/jats:styled-content>\n                            \u2212),\n                            <jats:italic>n<\/jats:italic>\n                            \u2009=\u2009388 and those with\n                            <jats:styled-content style=\"fixed-case\">LVI<\/jats:styled-content>\n                            (\n                            <jats:styled-content style=\"fixed-case\">LVI<\/jats:styled-content>\n                            +),\n                            <jats:italic>n<\/jats:italic>\n                            \u2009=\u2009163.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:styled-content style=\"fixed-case\">LVI<\/jats:styled-content>\n                            + status was associated with high stage and grade\n                            <jats:styled-content style=\"fixed-case\">UTUC<\/jats:styled-content>\n                            and lymph node metastasis (\n                            <jats:italic>P<\/jats:italic>\n                            \u2009&lt;\u20090.001).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The 5\u2010year\n                            <jats:styled-content style=\"fixed-case\">CSS<\/jats:styled-content>\n                            and\n                            <jats:styled-content style=\"fixed-case\">MFS<\/jats:styled-content>\n                            rates were significantly worse in the\n                            <jats:styled-content style=\"fixed-case\">LVI<\/jats:styled-content>\n                            + group than in\n                            <jats:styled-content style=\"fixed-case\">LVI<\/jats:styled-content>\n                            \u2212 group (52.2 vs 84.5%,\n                            <jats:italic>P<\/jats:italic>\n                            \u2009&lt;\u20090.001 and 43.8 vs 82.7%,\n                            <jats:italic>P<\/jats:italic>\n                            \u2009&lt;\u20090.001, respectively).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            In multivariate analysis,\n                            <jats:styled-content style=\"fixed-case\">LVI<\/jats:styled-content>\n                            + status was an independent prognostic factor for\n                            <jats:styled-content style=\"fixed-case\">CSS<\/jats:styled-content>\n                            and\n                            <jats:styled-content style=\"fixed-case\">MFS<\/jats:styled-content>\n                            (\n                            <jats:italic>P<\/jats:italic>\n                            \u2009=\u20090.04 and\n                            <jats:italic>P<\/jats:italic>\n                            \u2009&lt;\u20090.001). These findings were confirmed for the\n                            <jats:styled-content style=\"fixed-case\">pN0<\/jats:styled-content>\n                            \/x patient subgroup (\n                            <jats:italic>n<\/jats:italic>\n                            \u2009=\u2009504,\n                            <jats:italic>P<\/jats:italic>\n                            \u2009&lt;\u20090.001).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            In the\n                            <jats:styled-content style=\"fixed-case\">pN0<\/jats:styled-content>\n                            \/x patient subgroup, we described a prognostic tool for\n                            <jats:styled-content style=\"fixed-case\">MFS<\/jats:styled-content>\n                            based on independent factors that permitted us to stratify patients into groups of high, intermediate or low risk of metastasis relapse.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            The presence of\n                            <jats:styled-content style=\"fixed-case\">LVI<\/jats:styled-content>\n                            was a strong predictor of a poor outcome for\n                            <jats:styled-content style=\"fixed-case\">UTUC<\/jats:styled-content>\n                            .\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            When a lymphadenectomy has not been achieved, the report of\n                            <jats:styled-content style=\"fixed-case\">LVI<\/jats:styled-content>\n                            status is crucial to identfiy those patients at higher risk for metastatic relapse.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.12116","type":"journal-article","created":{"date-parts":[[2013,4,12]],"date-time":"2013-04-12T07:48:44Z","timestamp":1365752924000},"page":"1199-1207","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy"],"prefix":"10.1111","volume":"111","author":[{"given":"Sophie","family":"Hurel","sequence":"first","affiliation":[{"name":"Department of Urology C\u00f4te de Nacre Hospital CHU Caen  Caen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[{"name":"Department of Urology la Piti\u00e9 Salpetri\u00e8re Hospital AP\u2010HP  Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Ouzzane","sequence":"additional","affiliation":[{"name":"Department of Urology Claude Huriez Hospital CHRU Lille  Lille"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Rozet","sequence":"additional","affiliation":[{"name":"Department of Urology Institut Mutualiste Montsouris  Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[{"name":"Department of Urology Cochin Hospital AP\u2010HP  Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Zerbib","sequence":"additional","affiliation":[{"name":"Department of Urology Cochin Hospital AP\u2010HP  Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis Arvin","family":"Berod","sequence":"additional","affiliation":[{"name":"Department of Urology Albert Michallon Hospital CHU Grenoble  Grenoble"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Ruffion","sequence":"additional","affiliation":[{"name":"Department of Urology CHU Lyon\u2010Sud  Lyon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Urology Edouard Herriot Hospital CHU Lyon  Lyon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Cussenot","sequence":"additional","affiliation":[{"name":"Department of Urology Tenon Hospital AP\u2010HP  Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Houlgatte","sequence":"additional","affiliation":[{"name":"Department of Urology Val de Gr\u00e2ce Military Hospital  Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Ph\u00e9","sequence":"additional","affiliation":[{"name":"Department of Urology Foch Hospital  Suresnes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois\u2010Xavier","family":"Nouhaud","sequence":"additional","affiliation":[{"name":"Department of Urology Charles Nicolle Hospital CHU Rouen  Rouen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Bensadoun","sequence":"additional","affiliation":[{"name":"Department of Urology C\u00f4te de Nacre Hospital CHU Caen  Caen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francky","family":"Delage","sequence":"additional","affiliation":[{"name":"Department of Urology la Cavale Blanche Hospital CHU Brest  Brest"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Guillotreau","sequence":"additional","affiliation":[{"name":"Department of Urology Rangueil Hospital CHU Toulouse  Toulouse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Guy","sequence":"additional","affiliation":[{"name":"Department of Urology Gabriel\u2010Montpied Hospital CHU Clermont\u2010Ferrand  Clermont\u2010Ferrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Karsenty","sequence":"additional","affiliation":[{"name":"Department of Urology North Hospital AP\u2010HM  Marseille"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"De La Taille","sequence":"additional","affiliation":[{"name":"Department of Urology Henri Mondor Hospital AP\u2010HP  Creteil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Colin","sequence":"additional","affiliation":[{"name":"Department of Urology Claude Huriez Hospital CHRU Lille  Lille"},{"name":"Department of Urology Seclin Hospital  Seclin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"French Collaborative National Database on UTUC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,4,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.12.042"},{"key":"e_1_2_8_3_1","unstructured":"StenzlA WitjesJA Com\u00e9ratEet\u2009al.Guidelines on bladder cancer muscle\u2010invasive and metastatic 2012"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2361"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.12.029"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.04.032"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.08.019"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000181801.22474.8b"},{"key":"e_1_2_8_9_1","first-page":"1653","volume-title":"Campbell\u2010Walsh UROLOGY","author":"Sagalowsky A","year":"2007"},{"key":"e_1_2_8_10_1","first-page":"258","volume-title":"Renal Pelvis and Ureter. TNM Classification of Malignant Tumours Urological Tumours International Union Against Cancer","author":"Sobin L","year":"2009"},{"key":"e_1_2_8_11_1","volume-title":"International Histological Classification of Tumours: Histological Typing of Urinary Bladder Tumours","author":"Mostofi FK","year":"1973"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-012-0983-1"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.10.014"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07988.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464\u2010410X.2011.10893.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2453-9"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.11.058"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.01.008"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.09.036"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.03.142"},{"key":"e_1_2_8_21_1","first-page":"1159","article-title":"AFU recommendations 1998. \u2018Committee on Cancer of the French Association of Urology\u2019","volume":"12","author":"Rischmann P","year":"2002","journal-title":"Prog Urol"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.12116","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.12116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:55:57Z","timestamp":1761738957000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.12116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,12]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/bju.12116"],"URL":"https:\/\/doi.org\/10.1111\/bju.12116","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,12]]},"assertion":[{"value":"2013-04-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}